

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 11, 2026

NEURONETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-38546
(Commission
File Number)

33-1051425
(I.R.S. Employer
Identification No.)

3222 Phoenixville Pike, Malvern, PA
(Address of principal executive offices)

19355
(Zip Code)

Registrant's telephone number, including area code (877) 600-7555

(Former name or former address, if changed since last report.) Not applicable.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name on each exchange on which registered
Common Stock (\$0.01 par value)	STIM	The Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

Neuronetics, Inc. (the “Company”) issued a press release on August 11, 2026, announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is being furnished to the Securities and Exchange Commission (“SEC”) as Exhibit 99.1 to this report on Form 8-K and is incorporated by reference to this Item 2.02.

The information furnished pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.

Item 7.01 Regulation FD Disclosure.

On August 11, 2026, Neuronetics released a presentation (the “Presentation”) that it may present to certain investors. A copy of the Presentation is attached hereto as Exhibit 99.2. The information contained in Exhibit 99.2 is incorporated herein by reference.

The information in this report furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:

Certain statements in this report, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this report that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal year 2026 including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this report. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook TMS Inc. on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of

the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. For a discussion of these and other related risks, please refer to the Company's recent filings with the SEC, which are available on the SEC's website at www.sec.gov, including, without limitation, the factors described under the heading "Risk Factors" in Neuronetics' Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this report. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events, or changes in the Company's expectations.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release dated August 11, 2026 of Neuronetics, Inc.
99.2	Company Presentation August 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEURONETICS, INC.
(Registrant)

Date: August 11, 2026

By: /s/ Daniel L. Reuvers
Name: Daniel L. Reuvers
Title: President and Chief Executive Officer

Neuronetics

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the second quarter of 2026.

Second Quarter 2026 Financial Highlights

- Total revenue of \$41.6 million, up 9.1% compared to the second quarter of 2025
- Greenbrook revenue of \$26.9 million, up 16.8% compared to the second quarter of 2025
- Adjusted EBITDA of \$0.3 million compared to a loss of \$5.6 million in the second quarter of 2025
- Net loss of \$3.4 million compared to a loss of \$10.1 million in the second quarter of 2025
- Net cash used in operations and investing of \$1.4 million, a reduction of \$2.3 million compared to \$3.8 million in the second quarter of 2025

Recent Operational Highlights

- Nir Naor appointed as Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer
- Cory Anderson promoted to Executive Vice President/General Manager of Greenbrook clinics
- Rob Greene appointed as Senior Vice President, Sales

“This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing,” said Dan Reuvers, President and Chief Executive Officer of Neuronetics. “For some time, NeuroStar has not competed to its full potential, and we are changing that by broadening how customers can access our technology while we continue to drive operational gains across the Greenbrook clinics. We also strengthened our leadership team, adding proven talent in key roles. The combination of a leading TMS platform and a national care network is what sets Neuronetics apart, and it positions us to lead as new interventional therapies come to market. There is more work ahead, but I am encouraged by the traction we are beginning to demonstrate.”

Second Quarter 2026 Financial and Operating Results for the Three Months Ended June 30, 2026

	Revenues by Segments		
	Three Months Ended June 30,		
	2026	2025	
	Amount	Amount	% Change
(Unaudited; in thousands, except percentages)			
NeuroStar revenue	\$ 14,677	\$ 15,084	(2.7)%
Greenbrook revenue	26,891	23,024	16.8%
Total revenues	\$ 41,568	\$ 38,108	9.1%

Total revenue for the three months ended June 30, 2026 was \$41.6 million, an increase of \$3.5 million, or 9.1%, compared to the three months ended June 30, 2025 of \$38.1 million. The increase was primarily driven by higher Greenbrook revenue, which increased to \$26.9 million in the second quarter of 2026 from \$23.0 million in the second quarter of 2025, reflecting continued growth of the Greenbrook business.

Gross margin increased from 46.6% for the three months ended June 30, 2025 to 51.1% for the three months ended June 30, 2026. The increase in gross margin was driven by the positive impact of our new go-to-market strategy, as well as improved revenue cycle management within the Greenbrook clinics.

Operating expenses during the second quarter of 2026 were \$22.7 million, a decrease of \$3.1 million, or 12%, compared to \$25.8 million in the second quarter of 2025, primarily attributable to lower general and administrative expenses and lower sales and marketing expenses.

Loss from operations during the second quarter of 2026 was \$1.5 million, a decrease of \$6.6 million, as compared to a loss of \$8.1 million in the second quarter of 2025. Adjusted EBITDA during the second quarter of 2026 was \$0.3 million, an increase of \$5.9 million compared to a loss of \$5.6 million in the second quarter of 2025.

Net loss for the second quarter of 2026 was \$3.4 million, or \$0.05 per share, as compared to \$10.1 million, or \$0.15 per share, in the second quarter of 2025. Net loss per share was based on 73,129,107 and 66,180,069 weighted average common shares outstanding for the second quarters of 2026 and 2025, respectively.

As of June 30, 2026, the Company held \$25 million in total cash, consisting of cash and cash equivalents of \$19.2 million and \$5.8 million of restricted cash, compared to total cash of \$34.1 million as of December 31, 2025.

Strengthened Leadership Team

The Company made a series of changes to strengthen its senior leadership team and align its structure with the Company's priorities. Nir Naor was appointed Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer, bringing more than 20 years of finance leadership across medical device and care-delivery businesses, including experience guiding a company to profitability and positive cash flow. Cory Anderson, a five-year veteran of the Company, was promoted to Executive Vice President and General Manager of Greenbrook, reflecting the growing importance of the clinic business. Rob Greene joined as Senior Vice President, Sales, bringing extensive commercial leadership across healthcare and medical technology, including capital equipment and service, to support the Company's expanded NeuroStar go-to-market models.

Business Outlook

For the full year 2026, Neuronetics expects:

- Total revenue between \$160 million and \$164 million, as compared to prior guidance of \$160 million and \$166 million;
- Gross margin between 48% and 50%, as compared to prior guidance of 47% and 49%;
- Operating expenses between \$95 million to \$100 million, compared to prior guidance of \$100 million to \$105 million. Going forward, operating expense guidance will exclude stock-based compensation. On this basis, operating expenses are expected to be \$91 million to \$96 million, with estimated stock-based compensation of \$4 million.
- Cash flow from operations and investing in the range of negative \$10.5 million to negative \$14.5 million. This is compared to our prior guidance of cash flow from operations only in the range of negative \$13 million to negative \$17 million.

Non-GAAP Financial Measures (Unaudited)

Operating Expense Guidance: FY 2026

The following table presents the Company's reconciliation between Operating Expenses and Operating Expenses less Non-cash Stock- Based Compensation. This adjusted guidance is based on assumptions that management believes are reasonable under the circumstances. However, they are not necessarily indicative of the Company's future performance. Operating Expenses less Stock Based Compensation are projected Operating Expenses for the fiscal year 2026, less non-cash stock-based compensation.

	Range (in thousands)	
Operating expenses	\$ 95	\$ 100
Non-cash stock-based compensation expense ("SBC") ¹	\$ 4	\$ 4
Operating expenses, less SBC	\$ 91	\$ 96

- (1) Stock-based compensation consists of expenses related to restricted stock units and performance based restricted stock units. We exclude these expenses from our non-GAAP financial measures because they are non-cash charges that we do not consider reflective of our core ongoing operational performance. While share-based compensation is a recurring expense and a key part of our employee retention strategy, excluding it allows management and investors to compare our operational profitability more consistently against prior periods and industry peers.

Webcast and Conference Call Information

The conference call will be broadcast live in listen-only mode via webcast at <https://edge.media-server.com/mmc/p/7Tri4xna9>. To listen to the conference call on your telephone, participants may register for the call **here**. While it is not required, it is recommended you join 10 minutes prior to the event start

About Neuronetics

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar[®] Advanced Therapy system, the Company is a leading provider of transcranial magnetic stimulation ("TMS") treatment and, through Greenbrook TMS Inc. ("Greenbrook"), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO[®] therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder ("MDD") in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO[®] (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression ("TRD") in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit [NeuroStar.com](https://www.neurostar.com).

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:

Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal year 2026, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com

Media Contact:

EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

NEURONETICS, INC.
Consolidated Statements of Operations
(Unaudited; In thousands, except per share data)

	Three Months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
Revenues				
NeuroStar	\$14,677	\$ 15,084	\$ 27,602	\$ 28,400
Greenbrook	26,891	23,024	48,420	41,683
Total Revenue	41,568	38,108	76,022	70,083
Cost of revenues				
NeuroStar	3,312	4,311	6,170	7,461
Greenbrook	17,033	16,039	32,475	29,126
Total Cost of revenues	20,345	20,350	38,645	36,587
Gross profit	21,223	17,758	37,377	33,496
Operating expenses:				
Sales and marketing	9,984	11,868	20,721	23,867
General and administrative	11,404	12,150	24,452	25,287
Research and development	1,336	1,798	2,700	3,414
Total operating expenses	22,724	25,816	47,873	52,568
Loss from operations	(1,501)	(8,058)	(10,496)	(19,072)
Other (income) expense:				
Interest expense	2,125	1,969	4,391	3,891
Loss on extinguishment of debt	—	—	539	—
Other income, net	(162)	(188)	(1,182)	(435)
Net loss	\$ (3,464)	\$ (9,839)	\$ (14,244)	\$ (22,528)
Less: Net gain (loss) attributable to non-controlling interest	(25)	281	(15)	267
Net loss attributable to Neuronetics stockholders	(3,439)	(10,120)	(14,229)	(22,795)
Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders	\$ (0.05)	\$ (0.15)	\$ (0.20)	\$ (0.36)
Weighted average common shares outstanding, basic and diluted	73,129	66,180	71,369	63,835

NEURONETICS, INC.
Consolidated Balance Sheets
(Unaudited; In thousands, except per share data)

	June 30, 2026	December 31, 2025
<u>Assets</u>		
Current assets:		
Cash and cash equivalents	\$ 19,197	\$ 28,134
Restricted cash	5,750	6,000
Accounts receivable, net of allowance for credit losses of \$553 and \$1,043 as of June 30, 2026 and December 31, 2025, respectively	15,955	16,469
Inventory	5,502	4,327
Current portion of net investments in sales-type leases	233	225
Current portion of prepaid commission expense	2,773	3,050
Current portion of note receivables	315	424
Prepaid expenses and other current assets	3,505	2,922
Total current assets	<u>53,230</u>	<u>61,551</u>
Property and equipment, net	3,464	4,466
Goodwill	23,622	23,622
Intangible assets, net	17,420	18,149
Operating lease right-of-use assets	23,913	23,560
Net investments in sales-type leases	65	98
Prepaid commission expense	6,980	7,972
Long-term notes receivable	43	151
Other assets	2,792	1,982
Total assets	<u>\$ 131,529</u>	<u>\$ 141,551</u>
<u>Liabilities and Equity</u>		
Current liabilities:		
Accounts payable	\$ 12,419	\$ 10,739
Accrued expenses	8,929	12,316
Current portion of deferred revenue	1,143	753
Deferred and contingent consideration	250	500
Other payables	425	652
Current portion of operating lease liabilities	5,143	5,561
Total current liabilities	<u>28,309</u>	<u>30,521</u>
Long-term debt, net	61,519	65,807
Other long term liabilities	142	—
Deferred revenue	58	48
Operating lease liabilities	19,861	18,935
Total liabilities	<u>109,889</u>	<u>115,311</u>
Commitments and contingencies		
Equity:		
Preferred stock, \$0.01 par value: 10,000 shares authorized; no shares issued or outstanding on June 30, 2026 and December 31, 2025	—	—
Common stock, \$0.01 par value: 250,000 shares authorized; 76,193 and 68,994 shares issued and outstanding on June 30, 2026 and December 31, 2025, respectively	762	690
Additional paid-in capital	490,239	480,475
Accumulated deficit	(473,151)	(458,787)
Total Stockholders' equity	<u>17,850</u>	<u>22,378</u>
Non-controlling interest	3,790	3,862
Total equity	<u>21,640</u>	<u>26,240</u>
Total liabilities and equity	<u>\$ 131,529</u>	<u>\$ 141,551</u>

NEURONETICS, INC.
Consolidated Statements of Cash Flows
(Unaudited; In thousands)

	Six months ended June 30,	
	2026	2025
Cash flows from operating activities:		
Net loss	\$ (14,244)	\$ (22,528)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	1,474	1,812
Allowance for credit losses	(160)	83
Inventory impairment	—	177
Share-based compensation	2,365	3,258
Non-cash interest expense	478	388
Loss on extinguishment of debt	539	—
Loss on disposal of property and equipment	369	43
Changes in certain assets and liabilities:		
Accounts receivable, net	893	(2,479)
Inventory	(1,289)	(791)
Net investments in sales-type leases	24	12
Prepaid commission expense	1,268	613
Prepaid expenses and other assets	(647)	3,356
Accounts payable	1,572	(1,803)
Accrued expenses	(3,386)	(2,236)
Other liabilities	(85)	(320)
Deferred revenue	400	(82)
Net cash used in operating activities	<u>(10,429)</u>	<u>(20,497)</u>
Cash flows from investing activities:		
Purchases of property and equipment and capitalized software	(614)	(471)
Proceeds from the sale of property and equipment	25	—
Net cash used in investing activities	<u>(589)</u>	<u>(471)</u>
Cash flows from financing activities:		
Payments of debt issuance costs	(55)	—
Repayment of deferred and contingent consideration	(250)	—
Repayment of long-term debt	(5,000)	—
Payment for debt extinguishment costs	(250)	—
Proceeds from the issuance of common stock	—	20,700
Payments of common stock offering issuance costs	—	(1,731)
Proceeds from issuance of common stock under ATM Program	7,954	—
Payments of common stock offering issuance costs under ATM Program	(376)	—
Distribution to non-controlling interest	(192)	—
Proceeds from exercises of stock options	—	9
Net cash provided by financing activities	<u>1,831</u>	<u>18,978</u>
Net decrease in Cash, Cash equivalents and Restricted cash	(9,187)	(1,990)
Cash and cash equivalents and restricted cash and cash equivalents, beginning of period	34,134	19,459
Cash and cash equivalents and restricted cash and cash equivalents, end of period	<u>\$ 24,947</u>	<u>\$ 17,469</u>
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:		
Cash and cash equivalents	19,197	10,969
Restricted cash and cash equivalents	5,750	6,500
Total cash, cash equivalents and restricted cash	<u>\$ 24,947</u>	<u>\$ 17,469</u>

Non-GAAP Financial Measures (Unaudited)

EBITDA and adjusted EBITDA are not measures of financial performance under generally accepted accounting principles in the U.S. ("GAAP"), and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company's operations and to better understand its business. Further, management believes that the addition of the non-GAAP financial measures provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company's financial performance, results of operations and trends. The Company's calculation of EBITDA and adjusted EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment.

The following table reconciles reported net loss to EBITDA and adjusted EBITDA:

	Three Months ended		Six months ended	
	June 30,		June 30,	
	2026	2025	2026	2025
	(in thousands)		(in thousands)	
Net loss attributable to Neuronetics stockholders ¹	\$(3,439)	\$(10,120)	\$(14,229)	\$(22,795)
Interest expense, net	1,963	1,781	3,209	3,456
Income taxes	—	—	—	—
Depreciation and amortization	729	901	1,474	1,812
EBITDA	<u>\$ (747)</u>	<u>\$ (7,438)</u>	<u>\$ (9,546)</u>	<u>\$ (17,527)</u>
Stock based compensation (Note. 1)	688	1,814	2,365	3,258
Loss on extinguishment of debt (Note. 2)	—	—	539	—
Restructuring (Note. 3)	313	—	313	—
Adjusted EBITDA	<u>\$ 254</u>	<u>\$ (5,624)</u>	<u>\$ (6,329)</u>	<u>\$ (14,269)</u>

Footnotes

1. Stock-based compensation consists of expenses related to restricted stock units and performance based restricted stock units. We exclude these expenses from our non-GAAP financial measures because they are non-cash charges that we do not consider reflective of our core ongoing operational performance. While share-based compensation is a recurring expense and a key part of our employee retention strategy, excluding it allows management and investors to compare our operational profitability more consistently against prior periods and industry peers.
2. In connection with its \$5 million repayment of debt in the first quarter of 2026 to Perceptive Advisors, LLC, the Company recorded a total loss on partial debt extinguishment of approximately \$0.5 million. This infrequent and non-recurring expense is removed from EBITDA in order to provide a more accurate reflection of the Company's core operational performance for the period presented.
3. Restructuring expense represents net costs incurred in connection with leadership workforce reductions, role eliminations, or organizational restructuring activities, that are not expected to recur in the ordinary course of business. These costs have been added back to EBITDA because they are considered non-recurring and not reflective of the Company's ongoing operating performance. Management believes excluding these expenses provides a more meaningful measure of normalized earnings and period-to-period operating comparability.

References

¹ The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO. For more important safety information about SPRAVATO, please visit spravatohcp.com.



Neuronetics

COMPANY PRESENTATION

NASDAQ: STIM

August 2026

Forward Looking Statements

This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. ("Neuronetics" or the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data.

Certain statements in this presentation, including the documents incorporated by reference herein, include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and "forward-looking information" within the meaning of applicable Canadian securities laws. Statements in this presentation that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as "may," "will," "would," "should," "expect," "plan," "design," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "outlook" or "continue" as well as the negative of these terms and similar expressions. These statements include those relating to the Company's business outlook and current expectations for upcoming quarters and fiscal year 2026, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this presentation. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook TMS Inc. ("Greenbrook") on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. For a discussion of these and other related risks, please refer to the Company's recent filings with the U.S. Securities and Exchange Commission (the "SEC"), which are available on the SEC's website at www.sec.gov, including, without limitation, the factors described under the heading "Risk Factors" in Neuronetics' Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this presentation. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events, or changes in the Company's expectations.

Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with accounting principles generally accepted in the United States ("GAAP"), from time to time we may use or publicly disclose certain non-GAAP financial measures in the course of our financial presentations, earnings releases, earnings conference calls, and otherwise. For these purposes, the SEC defines a non-GAAP financial measure as a numerical measure of historical or future financial performance, financial positions, or cash flows that (i) exclude amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with GAAP in financial statements, and (ii) include amounts, or is subject to adjustments that effectively include amounts, that are excluded from the most directly comparable measure so calculated and presented.

Non-GAAP financial measures are provided as additional information to investors to provide an alternative method for assessing our financial condition and operating results. We believe that these non-GAAP measures, when taken together with our GAAP financial measures, allow us and our investors to better evaluate our performance and profitability. These measures are not in accordance with, or a substitute for, GAAP, and may be different from or inconsistent with non-GAAP financial measures used by other companies. These measures should be used in addition to and in conjunction with results presented in accordance with GAAP, and should not be relied upon to the exclusion of GAAP financial measures.

Pursuant to the requirements of Regulation G, whenever we refer to a non-GAAP financial measure, we will also generally present, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference with such comparable GAAP financial measure.

Neuronetics

The leading platform for delivering in-office mental health therapies when common anti-depressants fail

253,412

Unique Patients Treated¹

9,133,855

Treatments Administered¹

\$149M

Annual Revenue (2025)

Neuronetics

¹ Neuronetics, Inc. internal estimate based on the Company's data on total treatment sessions and patients treated.

Seasoned Senior Leadership Team



Dan Reuvers
President & CEO



Nir Naor
Chief Financial Officer



Cory Anderson
Executive Vice President
and General Manager of
Greenbrook



Rob Greene
Senior Vice President
of Sales



A Leader in Mental Health Care

Through its nationwide network of customers and company-run clinics, Neuronetics is facilitating access to leading therapies for mental health conditions.

Neuronetics



Neuronetics

*Psychedelics are not yet commercially available and pending FDA approval

Over 29 Million Lives Affected by Depression^{1,2,3}



U.S. Adults and Adolescents (ages 15-21) suffering from depression, depression with anxiety and OCD

What is MDD?

Major depressive disorder is persistent low mood or loss of interest lasting two weeks or more, enough to disrupt daily life.

How does it present in patients?

Low mood, loss of interest, and changes in sleep, appetite, energy, and concentration, sometimes with thoughts of death or suicidal ideation.

How can MDD affect patients?

- Impairs work, relationships, and daily function
- A leading cause of disability
- Often recurrent, with high relapse risk


Neuronetics

Adult Depression (MDD) 21million + Adolescent Depression 4.3 million + OCD 4 million ¹ NIMH <https://www.nimh.nih.gov/health/statistics/major-depression.shtml>, accessed 4/29/2024. ⁽²⁾ Depression- Pharma Intelligence Disease Analysis, www.datamonitorforhealthcare.com, Publication Date: June 2021. ⁽³⁾ Harvard Medical School, 2007. National Comorbidity Survey (NCSSC).

8 Million Patients are Poorly Served by Medication^{1,2,3,4,5}


First-line medical management via anti-depressants has significant limitations

Antidepressants have limited effectiveness



Patients' chances for remission decreases with each subsequent medication attempt

Antidepressants have material side effects



Discontinuation of medication increases with each new drug due to impact of side effects

Innovative In-Office Therapies

Offering two rapidly growing therapies for treatment resistant depression (TRD) when common anti-depressants fail

Transcranial Magnetic Stimulation (TMS)



NeuroStar®
Advanced Therapy for Mental Health

+23%

**Growth in Patients
Treated with TMS
in 2025¹**

Nasal Esketamine Spray



Spravato®
(esketamine) 
28 mg nasal spray

+57%

**Growth in
Spravato Revenue
in 2025²**

Neuronetics

¹ US Procedures based on 2026 Definitive Healthcare INC. w/ +7% increase to account for cash pay not captured in billing data.
² As reported by Johnson & Johnson for year ended Dec 31, 2025

NeuroStar TMS

The industry's leading TMS therapeutic platform



83%
measurable relief¹

62%
full remission²

36
daily sessions

19 min
per session



How it works

TMS uses focused magnetic pulses to gently activate brain circuits involved in mood, helping them function more normally over time.



Treatment course

A typical course is 36 daily sessions, with sessions as short as 19 minutes.



Safety and experience

Not a drug, surgery, or ECT "shock therapy". No sedation, and patients resume normal activities right after each session; side effects are typically mild scalp discomfort or headache.



Access and coverage

FDA-cleared and covered by most major insurers for patients who qualify.

Neuronetics

1. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. *Journal of Affective Disorders*, 277(12):65-74.
2. Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. *Depression and Anxiety*, 29(7):587-596.

Spravato

Approved for use as monotherapy or in combination with existing antidepressants



24 hr

Results as early as 24 hours¹

52%

remission at 4 weeks²

2 doses

for two weeks

2

hour treatments



How it works

Prescription nasal spray that is believed to target glutamate, working differently from standard antidepressants.



Treatment course

Twice weekly for four weeks, then weekly or every other week, in a certified office.



Safety and experience

Supervised dosing with at least 2-hours of monitoring; the majority of side effects resolved on the day of dosing.



Access and coverage



FDA-approved and covered by most major insurers with prior authorization.

Neuronetics

¹ SPRAVATO Prescribing Information, Janssen Pharmaceuticals, Inc. Revised 2025. Section 14, Clinical Studies.
² SPRAVATO (esketamine) Summary of Product Characteristics. European Medicines Agency.


Deploying Therapies Through Unique, Scaled Model

Mix of company-owned sites and NeuroStar TMS customers facilitates widespread patient access



92 Clinics Nationwide


NeuroStar TMS Customers



800+ Sites Nationwide

Greenbrook Mental Wellness Centers

Referred patients are evaluated, matched to the right therapy, and managed over time



Offering both therapies within a single clinic enables continuity of care. Treatment is individualized at initiation and adjusted over time, managed within one integrated care relationship.

Greenbrook: A Leading Platform for Emerging Therapies

Greenbrook's infrastructure can support additional novel therapies as they reach the market

Greenbrook

Proven REMS¹ infrastructure, built through Spravato experience



REMS launch experience



Certified sites



Trained staff



Benefits & prior-auth



National footprint



Available capacity



Potential Near-Term Psychedelic Opportunities²

COMP360 psilocybin for MDD

First-ever psychedelic offering for depression · Existing Compass Pathways collaboration



Phase 3 trial complete



FDA decision expected
year-end 2026



Preparing 2027
commercial rollout



Additional psychedelic-class therapies in development TRD, including post-traumatic stress disorder and anxiety

Uniquely positioned to be at the forefront of psychedelic therapy administration

Neuronetics

¹ REMS (Risk Evaluation and Mitigation Strategy): an FDA-required safety program mandating certified sites, trained staff, and supervised in-office administration.

² Psychedelics are not yet commercially available and pending FDA approval

NeuroStar: Evolving our Go-to-Market Approach

Three ways to access NeuroStar, broadening reach while preserving high-touch support

From one model to three

Our Treatment Session model, high-touch and ongoing, set NeuroStar apart, but did not fit every customer. Now customers choose which economic best fits their needs.



SESSIONS

Partnership

Our established treatment-session model, retaining the high-touch support that has always distinguished NeuroStar.

Upfront: None

Support: Full



LEASE

Finance It

Use the system over time with no significant upfront commitment, broadening the set of customers we can reach.

Upfront: Low

Support: À la carte



CAPITAL

Own It Outright

Purchase the system directly, with support available à la carte, allowing customers to choose the elements they value most.

Upfront: High

Support: À la carte

Competing across a broader set of customers than ever before, while preserving the support that sets us apart.

Poised to Deliver Strong Growth While Improving Cash Flow

FY 2026 Guidance

(As of August 11th, 2026)

Revenue **\$160M to \$164M (+7% to +10% YoY)**

Gross Margin **Between 48% and 50%**

Operating Expenses **\$91M - \$96M**
excluding ~\$4 million of non-cash stock-based compensation

Cash Flow **Cash Flow from Operations and Investing: \$(10.5)M to \$(14.5)M**

Reconciliation Bridge Operating Expense to Operating Expense less Non-Cash Stock-Based Compensation

(\$ in millions)

The following table presents the Company's reconciliation between Operating Expenses and Operating Expenses less Stock Based Compensation. This adjusted guidance is based on assumptions that management believes are reasonable under the circumstances. However, they are not necessarily indicative of the Company's future performance. Operating Expenses less Stock Based Compensation are projected Operating Expenses for the fiscal year 2026, less non-cash stock-based compensation.

FY 2026 Guidance: Operating Expenses

	Range	
Operating expenses	\$ 95	\$ 100
Non-cash stock-based compensation expense ("SBC") ⁽¹⁾	\$ (4)	\$ (4)
Operating expenses, less SBC	\$ 91	\$ 96

(1) Stock-based compensation consists of expenses related to restricted stock units and performance based restricted stock units. We exclude these expenses from our non-GAAP financial measures because they are non-cash charges that we do not consider reflective of our core ongoing operational performance. While share-based compensation is a recurring expense and a key part of our employee retention strategy, excluding it allows management and investors to compare our operational profitability more consistently against prior periods and industry peers.


Financial Overview

Worldwide Quarterly Revenue¹

(\$ in millions)

(As Reported)

Q2 2026 Revenue of \$41.6M, a 9% increase from Q2 2025



Neuronetics

(1) Actual results as reported and filed with the SEC for Neuronetics

Results of Operations¹

(\$ in thousands)

(As Reported)

	Three Months Ended June 30,	
	2025	2026
Revenues	\$38,108	\$41,568
<i>YOY Growth</i>		9%
Gross Profit	\$17,758	\$21,223
<i>Gross Margin</i>	47%	51%
Total Operating Expenses	\$25,816	\$22,724
<i>% of Revenues</i>	68%	55%
Loss from Operations	(\$8,058)	(\$1,501)
<i>% of Revenues</i>	-21%	-4%
Adjusted EBITDA	(\$5,624)	\$254
Net Loss	(\$10,120)	(\$3,439)
Cash	\$17,469	\$24,947

Neuronetics

(1) Actual results as reported and filed with the SEC for Neuronetics except for adjusted EBITDA which is a Non-GAAP metric

Reconciliation Bridge EBITDA to Adjusted EBITDA

(\$ in thousands)

The following table presents the Company's reconciliation between EBITDA and adjusted EBITDA. These pro forma results are based on assumptions that management believes are reasonable under the circumstances. However, they are not necessarily indicative of the Company's future performance. Earnings before interest, taxes, depreciation, and amortization ("EBITDA") is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization. Adjusted EBITDA ("Adjusted EBITDA") is defined as EBITDA, excluding the following items: stock based compensation, loss on extinguishment of debt, and other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently.

	Three Months Ended June 30,	
	2025	2026
Net Loss to STIM Shareholders¹	(\$10,120)	(\$3,439)
Interest Expense, Net	\$1,781	\$1,963
Depreciation and Amortization	\$901	\$729
EBITDA	(\$7,438)	(\$747)
Stock Based Compensation ¹	\$1,814	\$688
Restructuring ²		\$313
Adjusted EBITDA	(\$5,624)	\$254

(1) Stock-based compensation consists of expenses related to restricted stock units and performance based restricted stock units. We exclude these expenses from our non-GAAP financial measures because they are non-cash charges that we do not consider reflective of our core ongoing operational performance. While share-based compensation is a recurring expense and a key part of our employee retention strategy, excluding it allows management and investors to compare our operational profitability more consistently against prior periods and industry peers.

(2) Restructuring expense represents net costs incurred in connection with leadership workforce reductions, role eliminations, or organizational restructuring activities that are not expected to recur in the ordinary course of business. These costs have been added back to EBITDA because they are considered non-recurring and not reflective of the Company's ongoing operating performance. Management believes excluding these expenses provides a more meaningful measure of normalized earnings and period-to-period operating comparability.

Financial Position

(\$ in thousands)

	As of June 30, 2026
Cash and Cash Equivalents	\$19,197
Restricted Cash	\$5,750
Total Cash	\$24,947
Total Current Assets	\$53,230
Total Assets	\$131,529
Total Current Liabilities	\$28,309
Long-Term Debt, net	\$61,519
Total Liabilities	\$109,889
Accumulated Deficit	(\$473,151)
Total Stockholders' Equity	\$17,850

NeuroStar Indications and Safety Information

NeuroStar Adult Indications for Use

The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy System is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

NeuroStar Adolescent Indications for Use

NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of Major Depressive Disorder (MDD) in adolescent patients (15-21).

Important Safety Information

NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients' results may vary.

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).

Visit neurostar.com for full safety and prescribing information.

SPRAVATO® Indications and Safety Information

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SPRAVATO®?

SPRAVATO® can cause serious side effects, including:

- **Sedation, dissociation, and respiratory depression.** SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), and breathing problems (respiratory depression and respiratory arrest).
 - Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
 - Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.
- **Abuse and misuse.** There is a risk for abuse and misuse with SPRAVATO®, which may lead to physical and psychological dependence. Your healthcare provider should check you for signs of abuse, misuse, and dependence before and during treatment.
 - Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
 - Your healthcare provider can tell you more about the differences between physical and psychological dependence in drug addiction.
- **SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS).** Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (such as medical offices and clinics) must be enrolled in the program.

- **Increased risk of suicidal thoughts and actions.** Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, **especially within the first few months of treatment or when the dose is changed. SPRAVATO® is not for use in children.**

- Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.

- **How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?**

- Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
- Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
- Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.

- **Tell your healthcare provider or get emergency help right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:**

- | | |
|---|---|
| • thoughts about suicide or dying | • suicide attempts |
| • new or worse depression | • new or worse anxiety |
| • feeling very agitated or restless | • panic attacks |
| • trouble sleeping (insomnia) | • new or worse irritability |
| • acting aggressive, being angry or violent | • acting on dangerous impulses |
| • an extreme increase in activity and talking (mania) | • other unusual changes in behavior or mood |

SPRAVATO® Indications and Safety Information

What should I avoid while taking SPRAVATO®?

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See **"What is the most important information I should know about SPRAVATO®?"**

What are the possible side effects of SPRAVATO®?

SPRAVATO® may cause serious side effects including:

See **"What is the most important information I should know about SPRAVATO®?"**

Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.

Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.

Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.

The most common side effects of SPRAVATO® include:

- feeling disconnected from yourself, your thoughts, feelings and things around you
- dizziness
- nausea
- feeling sleepy
- spinning sensation
- decreased feeling of sensitivity (numbness)
- feeling anxious
- lack of energy

- increased blood pressure
- vomiting
- feeling drunk
- headache
- feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side effects to Johnson & Johnson at 1-800-526-7736, or to the FDA at 1-800-FDA-1088.

What is SPRAVATO® (esketamine) CIII nasal spray?

SPRAVATO® is a prescription medicine used:

- with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD)
- with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

SPRAVATO® Indications and Safety Information

Do not take SPRAVATO® if you:

- have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
- have an abnormal connection between your veins and arteries (arteriovenous malformation)
- have a history of bleeding in the brain
- are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®.

Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:

- have heart or brain problems, including:
 - high blood pressure (hypertension)
 - slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting
 - history of heart attack
 - history of stroke
 - heart valve disease or heart failure
 - history of brain injury or any condition where there is increased pressure in the brain
- have liver problems
- have ever had a condition called “psychosis” (see, feel, or hear things that are not there, or believe in things that are not true).
- are pregnant or plan to become pregnant. SPRAVATO® may harm your unborn baby. You should not take SPRAVATO® if you are pregnant.
 - Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®.
- If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®.

- There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at <https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/>.

- are breastfeeding or plan to breastfeed. SPRAVATO® passes into your breast milk. You should not breastfeed during treatment with SPRAVATO®.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicine may cause side effects.

Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicine. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I take SPRAVATO®?

- You will take SPRAVATO® nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device.
- Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.
- Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.
- During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.
- You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.
- If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.
- Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.
- If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.

Neuronetics

SPRAVATO® is a trademark of Janssen Pharmaceuticals, Inc. Learn more at [Spravato.com](https://spravato.com). Visit [Spravato.com](https://spravato.com) for full safety and prescribing information.